TABLE OF CONTENTS
1 INTRODUCTION 22
1.1 OBJECTIVES OF THE STUDY 22
1.2 MARKET DEFINITION 22
1.3 OVERVIEW 22
1.4 LIMITATIONS 24
1.5 MARKETS COVERED 24
2 MARKET SEGMENTATION 26
2.1 MARKETS COVERED 26
2.2 GEOGRAPHICAL SCOPE 27
2.3 YEARS CONSIDERED FOR THE STUDY 28
2.4 CURRENCY AND PRICING 28
2.5 DBMR TRIPOD DATA VALIDATION MODEL 29
2.6 MULTIVARIATE MODELLING 32
2.7 PRODUCT TYPE LIFELINE CURVE 32
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 33
2.9 DBMR MARKET POSITION GRID 34
2.10 MARKET END USER COVERAGE GRID 35
2.11 VENDOR SHARE ANALYSIS 36
2.12 SECONDARY SOURCES 37
2.13 ASSUMPTIONS 37
3 EXECUTIVE SUMMARY 38
4 PREMIUM INSIGHTS 41
4.1 PORTERS FIVE FORCES MODEL 42
4.2 PESTEL ANALYSIS 43
5 INDUSTRY INSIGHTS: MIDDLE EAST & AFRICA NASAL SPRAY MARKET 44
5.1 INDUSTRY INSIGHTS 44
6 REGULATIONS: MIDDLE EAST & AFRICA NASAL SPRAY MARKET 45
7 MARKET OVERVIEW 46
7.1 DRIVERS 48
7.1.1 INCREASE IN INFECTION AND ALLERGIC CASES 48
7.1.2 RISING PREVALENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA 48
7.1.3 EFFECTIVENESS OVER OTHER FORMS OF DRUG DELIVERY 49
7.1.4 IMPROVING PATIENT COMPLIANCE AND ACCEPTABILITY 50
7.2 RESTRAINTS 51
7.2.1 PRODUCT RECALLS 51
7.2.2 ADVERSE EFFECTS OF USING NASAL SPRAYS 52
7.3 OPPORTUNITIES 53
7.3.1 NEW RISING DEMAND FOR SELF-ADMINISTRATIVE DRUG DELIVERY 53
7.3.2 EXPANDING THERAPEUTIC APPLICATIONS FOR NASAL SPRAYS 53
7.3.3 STRATEGIC INITIATIVES TAKEN BY KEY MARKET PLAYERS 54
7.4 CHALLENGES 54
7.4.1 REGULATORY HURDLES 54
7.4.2 ADDICTION TO NASAL SPRAY 55
8 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY PRODUCT TYPE 56
8.1 OVERVIEW 57
8.2 DECONGESTION NASAL SPRAY 60
8.3 STEROID NASAL SPRAY 61
8.4 SALT WATER SOLUTION/SALINE NASAL SPRAY 62
8.5 OTHERS 63
9 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY CONTAINER DESIGN 64
9.1 OVERVIEW 65
9.2 PUMP BOTTLES 68
9.3 PRESSURIZED CANISTERS 69
10 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY DOSAGE FORM 70
10.1 OVERVIEW 71
10.2 MULTI DOSE 74
10.3 UNIT/SINGLE DOSE 75
10.4 BI DOSE 76
11 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS 78
11.1 OVERVIEW 79
11.2 ANTIHISTAMINE 82
11.3 NASAL STEROIDS 83
11.4 MAST CELL INHIBITOR 84
11.5 ANTICHOLINERGIC 85
12 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY APPLICATION 86
12.1 OVERVIEW 87
12.2 NASAL CONGESTION 90
12.3 ALLERGIC AND NON-ALLERGIC RHINITIS 91
12.4 CENTRAL NERVOUS SYSTEM DISORDERS 92
12.5 VACCINATION 93
12.6 OTHERS 94
13 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY 95
13.1 OVERVIEW 96
13.2 PRESCRIBED 99
13.3 OVER THE COUNTER 100
14 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY END USER 102
14.1 OVERVIEW 103
14.2 HOME CARE SETTINGS 106
14.3 HOSPITALS 107
14.4 CLINICS 108
14.5 COMMUNITY HEALTH CARE 109
15 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY REGION 110
15.1 MIDDLE EAST AND AFRICA 111
15.1.1 SOUTH AFRICA 118
15.1.2 UAE 120
15.1.3 SAUDI ARABIA 122
15.1.4 REST OF MIDDLE EAST & AFRICA 124
16 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, COMPANY LANDSCAPE 125
16.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 125
17 SWOT ANALYSIS 126
18 COMPANY PROFILE 127
18.1 GLAXOSMITHKLINE PLC. 127
18.1.1 COMPANY SNAPSHOT 127
18.1.2 REVENUE ANALYSIS 127
18.1.3 COMPANY SHARE ANALYSIS 128
18.1.4 PRODUCT PORTFOLIO 128
18.1.5 RECENT DEVELOPMENTS 128
18.2 PFIZER INC. 130
18.2.1 COMPANY SNAPSHOT 130
18.2.2 REVENUE ANALYSIS 130
18.2.3 COMPANY SHARE ANALYSIS 131
18.2.4 PRODUCT PORTFOLIO 131
18.2.5 RECENT DEVELOPMENTS 131
18.3 EMERGENT 133
18.3.1 COMPANY SNAPSHOT 133
18.3.2 REVENUE ANALYSIS 133
18.3.3 COMPANY SHARE ANALYSIS 134
18.3.4 PRODUCT PORTFOLIO 134
18.3.5 RECENT DEVELOPMENT 134
18.4 SANDOZ INTERNATIONAL GMBH (A PART OF NOVARTIS) 135
18.4.1 COMPANY SNAPSHOT 135
18.4.2 REVENUE ANALYSIS 135
18.4.3 COMPANY SHARE ANALYSIS 136
18.4.4 PRODUCT PORTFOLIO 136
18.4.5 RECENT DEVELOPMENT 136
18.5 CATALENT, INC. 137
18.5.1 COMPANY SNAPSHOT 137
18.5.2 REVENUE ANALYSIS 137
18.5.3 COMPANY SHARE ANALYSIS 138
18.5.4 PRODUCT PORTFOLIO 138
18.5.5 RECENT DEVELOPMENTS 138
18.6 AYTU HEALTH (A SUBSIDIARY OF AYTU BIOPHARMA, INC.) 140
18.6.1 COMPANY SNAPSHOT 140
18.6.2 REVENUE ANALYSIS 140
18.6.3 PRODUCT PORTFOLIO 141
18.6.4 RECENT DEVELOPMENTS 141
18.7 AISHWARYA GROUP 142
18.7.1 COMPANY SNAPSHOT 142
18.7.2 PRODUCT PORTFOLIO 142
18.7.3 RECENT DEVELOPMENTS 142
18.8 ASSERTIO THERAPEUTICS, INC. 143
18.8.1 COMPANY SNAPSHOT 143
18.8.2 REVENUE ANALYSIS 143
18.8.3 PRODUCT PORTFOLIO 144
18.8.4 RECENT DEVELOPMENT 144
18.9 AURENA LABORATORIES. 145
18.9.1 COMPANY SNAPSHOT 145
18.9.2 PRODUCT PORTFOLIO 145
18.9.3 RECENT DEVELOPMENTS 145
18.10 BAYER AG 147
18.10.1 COMPANY SNAPSHOT 147
18.10.2 REVENUE ANALYSIS 147
18.10.3 COMPANY SHARE ANALYSIS 148
18.10.4 PRODUCT PORTFOLIO 148
18.10.5 RECENT DEVELOPMENTS 148
18.11 CIPLA INC. 150
18.11.1 COMPANY SNAPSHOT 150
18.11.2 REVENUE ANALYSIS 150
18.11.3 PRODUCT PORTFOLIO 151
18.11.4 RECENT DEVELOPMENT 151
18.12 J PHARMACEUTICALS. 152
18.12.1 COMPANY SNAPSHOT 152
18.12.2 PRODUCT PORTFOLIO 152
18.12.3 RECENT DEVELOPMENTS 152
18.13 LEEFORD HEALTHCARE LTD 153
18.13.1 COMPANY SNAPSHOT 153
18.13.2 PRODUCT PORTFOLIO 153
18.13.3 RECENT DEVELOPMENTS 153
18.14 ST. RENATUS. 154
18.14.1 COMPANY SNAPSHOT 154
18.14.2 PRODUCT PORTFOLIO 154
18.14.3 RECENT DEVELOPMENTS 154
18.15 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD) 155
18.15.1 COMPANY SNAPSHOT 155
18.15.2 REVENUE ANALYSIS 155
18.15.3 PRODUCT PORTFOLIO 156
18.15.4 RECENT DEVELOPMENTS 156
18.16 ULTRATECH INDIA LIMITED 157
18.16.1 COMPANY SNAPSHOT 157
18.16.2 PRODUCT PORTFOLIO 157
18.16.3 RECENT DEVELOPMENTS 157
18.17 VIATRIS INC. 158
18.17.1 COMPANY SNAPSHOT 158
18.17.2 REVENUE ANALYSIS 158
18.17.3 COMPANY SHARE ANALYSIS 159
18.17.4 PRODUCT PORTFOLIO 159
18.17.5 RECENT DEVELOPMENT 159
19 QUESTIONNAIRE 160
20 RELATED REPORTS 164

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.